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Media reports suggested increased public demand for
anthrax prophylaxis after the intentional anthrax cases in
2001, but the magnitude of anthrax-related prescribing in
unaffected regions was not assessed. We surveyed a ran-
dom sample of 400 primary care clinicians in Minnesota
and Wisconsin to assess requests for and provision of
anthrax-related antimicrobial agents. The survey was
returned by 239 (60%) of clinicians, including 210 in outpa-
tient practice. Fifty-eight (28%) of those in outpatient prac-
tice received requests for anthrax-related antimicrobial
agents, and 9 (4%) dispensed them. Outpatient fluoro-
quinolone use in both states was also analyzed with regres-
sion models to compare predicted and actual use in
October and November 2001. Fluoroquinolone use as a
proportion of total antimicrobial use was not elevated, and
anthrax concerns accounted for an estimated 0.3% of all
fluoroquinolone prescriptions. Most physicians in
Minnesota and Wisconsin managed anthrax-related
requests without dispensing antimicrobial agents. 
U
ntil recently, human anthrax infections in the United
States have been rare and generally limited to agricul-
tural workers with exposure to infected animals or animal
products. The first bioterrorism-related cases of human
anthrax occurred in late 2001, when spore-laden envelopes
were mailed to news media facilities and government offi-
cials. Twenty-two cases of anthrax were identified from
October 4 to November 20, including 5 fatalities (1). Cases
occurred in New York, New Jersey, Pennsylvania,
Virginia, Maryland, Connecticut, and Florida. The patients
included targeted persons, people who worked with target-
ed persons, postal workers, and people who were exposed
along the mail route of spore-containing envelopes. 
At the affected sites, ≈10,000 people were advised to
take antimicrobial prophylaxis for at least 60 days to pre-
vent anthrax, and an estimated 32,000 people initiated
antibiotic prophylaxis (1,2). Most persons received initial
prophylaxis with a fluoroquinolone (ciprofloxacin), a class
of drug that is also important for treatment of community-
acquired pneumonia and other serious infections (3,4). In
public announcements regarding anthrax, the Centers for
Disease Control and Prevention (CDC) emphasized the
overall low risk to the population but also endorsed actions
to minimize personal risk. These measures included not
opening suspicious mail, keeping mail away from the face
when opened, and washing hands after handling mail (5).
Although national publicity generated a high level of pub-
lic concern throughout the country, no evidence of anthrax
spore release was found in any other regions of the United
States.
Media reports in late 2001 reflected a high level of anx-
iety in the general public regarding anthrax. An ABC
News/Washington Post poll in mid-October 2001 found
that 65% of respondents were worried about letters con-
taminated with the anthrax bacteria, and 54% were worried
about an anthrax attack on themselves, their close friends,
or relatives (6). At the same time, anecdotal evidence sug-
gested that ciprofloxacin sales were increasing at some
pharmacies (7,8). New Web sites marketed ciprofloxacin
“prevention packs” to anxious consumers (9). However,
the magnitude of public demand for anthrax-related
antimicrobial agents and for physicians to dispense them
has not been assessed in regions of the country where no
cases or exposures occurred.
Inappropriate use of fluoroquinolones raises concern
for several reasons. They can potentially cause adverse
reactions, and excessive hoarding could contribute to drug
shortages. Fluoroquinolones are critical drugs for manag-
ing a variety of serious infections, and in recent years the
rate of resistance has increased among both gram-positive
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use of these agents (10–12). Recent fluoroquinolone use is
an independent risk factor for fluoroquinolone-resistant
pneumococcal infections (13). 
The purpose of this investigation was to assess patient
demand for anthrax prophylaxis and changes in fluoro-
quinolone use in late 2001 in a region of the country in
which no cases or exposures occurred. Clinicians were sur-
veyed regarding patient demand for anthrax prophylaxis
and use of prophylactic antimicrobial agents, and a com-
mercial database was analyzed to assess changes in overall
fluoroquinolone use. 
Methods
Clinician Survey
A 1-page survey and cover letter were mailed to 400
primary care clinicians in Minnesota and Wisconsin in
October 2002. Within each state, a simple random sample
of 200 clinicians was selected from among those with an
active medical license in any of the following specialties:
emergency medicine, family practice, general practice,
general internal medicine, pediatrics, nurse practitioner, or
physician assistant. The sampling frame was obtained
from the licensing agencies in each state and included
5,800 clinicians in Minnesota and 6,510 clinicians in
Wisconsin. Two reminder letters were sent to all survey
recipients to encourage participation.
The anonymous survey contained 12 questions to
obtain information on specialty, county of practice, outpa-
tient practice activity during the last quarter of 2001,
requests for anthrax prophylaxis from October through
December of 2001, and distribution of antimicrobials for
anthrax prophylaxis or stockpiling. Clinicians who indicat-
ed that they prescribed or distributed anthrax-related
antimicrobial agents were asked to specify the number and
types of people (i.e., patients, family members, acquain-
tances, self) who received the drugs, and the specific drugs
that were used. The occurrence of suspected anthrax-relat-
ed exposures was not assessed. Clinicians who indicated
they were not in full- or part-time outpatient medical prac-
tice from October through December of 2001 were asked
to return the survey without answering the other questions.
The survey procedures were reviewed and approved by
the institutional review board at Marshfield Clinic.
Outpatient Use of Antimicrobial Agents
The primary measures of fluoroquinolone use were
based on prescribing data (Xponent, IMS Health, Inc.,
Plymouth Meeting, PA) and volume retail distribution data
(DDD, IMS Health, Inc.) for the states of Wisconsin and
Minnesota. The prescribing and distribution data represent
independent measures of antimicrobial use that were
obtained to evaluate a statewide program to promote
appropriate antimicrobial use. Prescribing data were avail-
able for the years 2000 through 2002. Volume distribution
data were available for the years 1999 through 2002. For
this analysis, oral antimicrobial agents were grouped into
the following three categories: fluoroquinolones
(ciprofloxacin, levofloxacin, lomefloxacin, moxifloxacin,
ofloxacin), tetracyclines (doxycycline, tetracycline,
minocycline), and other oral antimicrobial agents (amoxi-
cillin, amoxicillin-clavulanate, ampicillin, cephalosporins,
extended-spectrum macrolides, macrolides, penicillin, and
trimethoprim-sulfamethoxazole). The first two categories
represented drug classes that were most likely to be used
for anthrax prophylaxis or stockpiling, since they were rec-
ommended as first-line agents by CDC (14). The third cat-
egory provided a measure of seasonal and annual trends in
outpatient use of antimicrobials, since the drugs in this cat-
egory (with the possible exception of penicillin and amox-
icillin) would not be appropriate for managing anthrax
exposure. Penicillin or amoxicillin use was recommended
for anthrax use only when the first-line agents were con-
traindicated, and it is therefore unlikely that a substantial
number of these prescriptions were generated for anthrax-
related concerns. Prescribing and volume distribution data
were not available for individual drugs within each class.
Only oral agents in solid (capsule or tablet) formulation
were included in the analyses to avoid including prescrip-
tions for young children. 
Xponent prescribing data included all dispensed pre-
scriptions in Minnesota or Wisconsin from licensed pre-
scribers. The total number of prescriptions written in each
state was available by month for the years 2000, 2001, and
2002. The prescribing databases were compiled by IMS
Health with proprietary methods. The Xponent prescribing
database was derived from transactional data provided by
59% of all retail pharmacies in Wisconsin and Minnesota,
including 65% of chain pharmacies and 51% of independ-
ent retail pharmacies. Prescriptions from unsampled stores
were estimated on the basis of prescription totals from
matched nearby stores with weighting to adjust for differ-
ences in total retail sales volume, which was available for
nearly all stores. Estimates were also weighted to account
for the distance between sampled stores and matched
unsampled stores, with closer stores contributing more to
the estimated prescription volume. The proportion of all
prescriptions in each state based on estimated data from
unsampled stores was 33%–37%. 
Retail distribution was measured based on the volume
of antimicrobial agents distributed to retail outlets on a
monthly basis for the years 1999 through 2002 (DDD data,
IMS Health, Inc.). Retail distribution data (measured in
kilograms) were ultimately derived from wholesalers and
distributors serving pharmacies in both states. Volume was
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patients, and distributed antimicrobial agents could be
returned to the wholesalers without being sold. In this sit-
uation, returned antimicrobial agents were subtracted from
the total distributed in a given month to yield the net retail
distribution for each drug class. As a result, the retail dis-
tribution data may overestimate or underestimate actual
distribution to patients, particularly in short time periods.
Inpatient pharmacies, prisons, veterinarians, nursing
homes, dialysis clinics, and federal government sites were
excluded from the volume distribution data. The DDD
database captured 93% of actual volume of antimicrobial
distribution in these states.
Statistical Analysis
To account for the state-level sampling in the clinician
survey, analysis weights were generated for each survey
responder. These weights were computed by multiplying
the inverse of the sampling probability for each responder
by the inverse of the response rate in the appropriate state.
Weighted analyses for complex sample designs were per-
formed by using the SAS 8.2 (SAS Institute Inc., Cary,
NC) and SUDAAN 8.0 (RTI International, Research
Triangle Park, NC) software. The impact of the weighting
was minimal in our study; estimated percents for the
weighted and unweighted analyses differed by <l percent-
age point. We therefore present unweighted point esti-
mates, except for the estimate of anthrax-related
antimicrobial drug prescribing. All statistical tests for the
clinician survey were based on weighted data to reflect the
complex sample design. Categorical variables were com-
pared by using the chi-square test.
For the Xponent prescribing data, we fit models for the
absolute number and proportion of prescriptions for fluo-
roquinolones and tetracyclines. Absolute numbers of pre-
scriptions were modeled by using linear regression, while
proportions of prescriptions were modeled by using nega-
tive binomial regression. All of the models contained cate-
goric effects for year and month and indicator variables for
October, November, and December of 2001. We generated
predictions for the fourth quarter of 2001 by computing
linear combinations of the appropriate parameters from the
above models. The modeling procedures for the DDD data
were the same as those for the Xponent data, except that
we modeled total retail distribution volume by month for
each drug category.
Results
Clinician Survey
Surveys were returned by 239 (60%) of 400 clinicians,
including 123 in Wisconsin and 116 in Minnesota. Twenty-
nine (12%) of the 239 respondents were excluded from
subsequent analyses because they were not engaged in full-
or part-time outpatient practice during the last 3 months of
2001. The respondent medical practices were located in 68
counties; 58 (28%) practices were located in the 11-county
Minneapolis–St. Paul metropolitan area, and 24 (11%)
were located in the 4-county Milwaukee-Waukesha metro-
politan area. One hundred fifty-seven (75%) were physi-
cians (MD or DO), and 52 (25%) were nurse practitioners
or physician assistants. Physician specialties included fam-
ily practice (42%), internal medicine (30%), pediatrics
(18%), emergency medicine (4%), and other (6%).
Fifty-eight (28%) of the clinicians reported that some-
one had asked them to prescribe an antimicrobial drug to
prevent anthrax or stockpile in case of future bioterrorist
attacks. Physicians were significantly more likely than
nonphysicians to receive requests for antimicrobial agents
(Table). The occurrence of patient requests by state, prac-
tice specialty, or practice location (Minneapolis–St. Paul
and Milwaukee–Waukesha metropolitan areas vs. other
areas) did not differ significantly.
Nine (4%) of the clinicians provided antimicrobial
agents to 11 persons for anthrax prevention or stockpiling.
Seven clinicians provided such agents for a single person,
and 2 clinicians provided them for 2 persons. All 9 clini-
cians were MDs or DO, and 8 (89%) practiced in
Wisconsin. Among 58 clinicians who received such
requests, 8 (14%) provided them; 1 additional clinician did
not receive requests but provided these drugs for family
members. Nine (82%) of the 11 courses of antimicrobial
agents were given to patients seen in the clinician’s prac-
tice, and 2 were given to family members. One clinician
reported that prophylactic antimicrobial agents were given
to a patient who had exposure to a building in Washington,
D.C., where anthrax release was confirmed; the risk for
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fluoroquinolone (levofloxacin or ciprofloxacin) was used
for 10 (91%) of the 11 courses; amoxicillin was given to 1
person. No other classes of antimicrobial agents were used.
Survey responses were used to estimate the total num-
ber of anthrax-related fluoroquinolone prescriptions writ-
ten in Wisconsin and Minnesota during the last quarter of
2001. State medical licensing records indicate that ≈10,807
primary care clinicians were engaged in full- or part-time
outpatient practice in Minnesota and Wisconsin at that
time. If the survey responses are representative of this
group, an estimated 420 clinicians (3.9%) in these states
provided anthrax-related antimicrobial agents. The 95%
confidence intervals (CI) for this proportion are 1.2% and
6.5%, corresponding to 135 and 706 clinicians, respective-
ly. The total number of anthrax-related courses of antimi-
crobial agents prescribed during the last quarter of 2001
was estimated to be 523 (95% CI, 394–653) in the two
states. If these prescriptions were mostly for fluoro-
quinolones, they would have represented ≈0.3% of all flu-
oroquinolone prescriptions written in Minnesota or
Wisconsin from October through December of 2001.
Outpatient Use of Antimicrobial Agents
The annual number of fluoroquinolone prescriptions in
Minnesota and Wisconsin increased 20% from 2000 to
2002, while the annual number of prescriptions declined
during this period for tetracycline drugs and other antimi-
crobials. In October 2001, the number of fluoroquinolone
prescriptions was 22% higher than in October 2000, and
the number of fluoroquinolone prescriptions exceeded the
95% CI based on the predictive model (Figure 1A). The
proportion of all antimicrobial prescriptions (excluding
tetracyclines) represented by fluoroquinolones gradually
increased from 2000 to 2002, and this proportion was
higher in October 2001 (17.5%) than in October 2000
(15.5%). However, the observed proportion of fluoro-
quinolone prescriptions was lower than predicted in
October and November of 2001, after adjusting for the sec-
ular trend (Figure 1B). Retail distribution of oral fluoro-
quinolones was significantly elevated in October and
November of 2001 (Figure 2A). The fluoroquinolone pro-
portion of total retail distribution of antimicrobial agents
(excluding tetracyclines) also increased significantly in
October 2001, but it was lower than predicted in
November (Figure 2B).
The proportion of all antimicrobial prescriptions
(excluding fluoroquinolones) that were for tetracyclines
was near the upper limit of the 95% CI in October 2001,
and it exceeded the upper limit in November 2001
(Figure 3). The proportion of antimicrobial drug retail
volume represented by tetracyclines was not elevated dur-
ing those months (data not shown). 
Discussion
The results of this study confirm that public demand for
anthrax-related antimicrobial agents was substantial in
Minnesota and Wisconsin, since one fourth of primary care
clinicians received requests for these drugs. We found that
physicians received these requests more often than non-
physicians. Despite requests from patients and family
members, relatively few antimicrobial agents were dis-
pensed for anthrax prophylaxis. Extrapolation of survey
responses to all primary care clinicians in Minnesota and
Wisconsin suggests that ≈500 anthrax-related antimicro-
bial drug courses were dispensed during the last quarter of
2001. Even if nearly all of these were fluoroquinolones,
the volume of anthrax-related fluoroquinolone use repre-
sented only a small fraction of total use in Minnesota and
Wisconsin during that period. 
The prescribing and retail distribution data showed
surges in fluoroquinolone use during October 2001, but
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Figure 1. A) Actual and predicted fluoroquinolone prescriptions,
January 2000 through December 2002. B) Actual and predicted
fluoroquinolone prescriptions as a percentage of all outpatient
antibiotic prescriptions, January 2000 through December 2002.
Tetracycline and related antimicrobial agents were excluded from
the denominator in each month. Vertical bars show 95% confi-
dence intervals. All models included categorical effects for year
and month and indicator variables for October, November, and
December, 2001. total use of antimicrobials also increased for unknown rea-
sons during that period. Fluoroquinolone prescriptions as a
proportion of all antimicrobial prescriptions were not ele-
vated, which was consistent with the findings from the cli-
nician survey. Although tetracycline/doxycycline
prescriptions as a proportion of all outpatient antimicrobial
prescriptions (excluding fluoroquinolones) were elevated
in October and November 2001, the clinician survey indi-
cated that this increase was unrelated to anthrax prescrib-
ing. None of the survey respondents reported using
tetracycline/doxycycline for this purpose, and
ciprofloxacin was the anthrax drug that received most
media attention in late 2001.
Two other studies have addressed national use of
antimicrobial agents following the anthrax cases in 2001.
In one study that used a national pharmacy claims data-
base, the rate of ciprofloxacin use increased 9.8% in
October 2001 relative to October 2000 (15). As expected,
the greatest increase in use was observed in New York, the
mid-Atlantic states, and Florida. Ciprofloxacin prescribing
rates were not reported for Minnesota or Wisconsin. In this
study, the denominator was defined as the number of cov-
ered persons who filled a prescription for any drug or eli-
gible health product during that month. As a result, the
observed rate differences may have been influenced by
both changes in the numerator (number of ciprofloxacin
prescriptions) and changes in the denominator (number of
persons filling any prescription). 
A similar study used IMS Health National Prescription
Audit Plus7 data to compare national ciprofloxacin use
from July to December of 2001 and 2000 (16).
Comparison drugs included oral azithromycin and
cefuroxime, which are commonly used in outpatient prac-
tice but not recommended for anthrax prophylaxis.
Ciprofloxacin prescriptions increased by 42%; cefuroxime
prescriptions declined by 3%. The results were not report-
ed by region, and they included prescriptions in New York,
Florida, and other affected regions. The authors did not
assess monthly ciprofloxacin prescriptions as a percentage
of all antimicrobial prescriptions. The results of our study
suggest that short-term variations in single drug prescrib-
ing should be interpreted with caution when the specific
diagnoses or prescribing indications are not known. We
found that a short-term increase in fluoroquinolone use in
Minnesota and Wisconsin was accompanied by an overall
increase in antimicrobial drug use. Thus, factors unrelated
to anthrax may have also contributed to the observed
increase in fluoroquinolone use during October 2001,
especially in unaffected regions of the United States. 
Whether patterns of antimicrobial use in Minnesota
and Wisconsin are generalizable to other unaffected
regions of the United States is not known. For example,
total ciprofloxacin prescriptions in October 2001
appeared to increase >25% in some unaffected states,
including Nevada, California, and New Mexico (15). No
information is available regarding the clinical indications
for these prescriptions, and how much of this increase can
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Figure 2. A) Retail distribution of fluoroquinolone antimicrobial
agents, January 1999 through December 2002. Volume was
measured in kilograms. B) Actual and predicted retail distribution
of fluoroquinolone antimicrobial agents as a percentage of total
antibiotic volume distribution (excluding tetracyclines), January
1999 through December 2002. Vertical bars show 95% confidence
intervals.
Figure 3. Actual and predicted tetracycline group prescriptions as
a percentage of all outpatient antimicrobial prescriptions (exclud-
ing fluoroquinolones), January 2000 through December 2002.
Vertical bars show 95% confidence intervals. be attributed to anthrax-related prescribing is unclear.
Other factors may also contribute to regional differences
in prescribing, since physicians in the northeastern and
southern United States are more likely to prescribe broad-
spectrum antimicrobials than those in the midwestern or
western regions (17).
The survey results in Minnesota and Wisconsin may
have underestimated actual anthrax-related prescribing,
since clinicians who dispensed antimicrobial agents may
have been reluctant to return the survey. However, the
cover letter and survey questions were neutral regarding
the appropriateness of antimicrobial drug use, and the sur-
vey was anonymous. Poor recall is another potential
source of error, since the survey was conducted approxi-
mately 1 year after the first cases of intentional anthrax
occurred. Because we were asking about unusual events
that were outside the scope of normal clinical practice, we
assumed that clinicians would still recall any anthrax-relat-
ed prescribing. Finally, the survey results did not allow us
to determine if patients consumed these agents for anthrax
prophylaxis, or if they were stockpiled for future use.
The human anthrax cases in 2001 and the related events
illustrate how quickly demand for a critical drug can esca-
late as a result of heightened public anxiety and media
attention. Most physicians in Minnesota and Wisconsin
managed public and patient expectations without dispens-
ing antimicrobial agents. However, social factors clearly
influence prescribing decisions (18), and effective public
and physician communication will be essential to promote
rational behavior if similar or more extreme situations
arise in the future. A communications strategy should be
developed in advance that includes identifying key experts
at the state and national level for news media communica-
tions and devising a plan for coordination and consistency
of messages from different agencies.
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